Antileishmanial structure-activity relationships of synthetic phospholipids: In vitro and in vivo activities of selected derivatives

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4525-4528

  Seifert, Karin ^a   Lemke, Andreas ^b   Croft, Simon L ^a   Kayser, Oliver ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; D 20317; D 20681; D 21298; D 21381; D 21573; D 21636; D 21719; D 21720; D 22084; D 22207; D 22455; D 22642; D 22827; D 22829; D 22830; D 22883; D 23156; D 23167; D 23261; D 23322; D 24062; MILTEFOSINE; PERIFOSINE; PHOSPHOLIPID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; MAMMAL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CRICETINAE; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LETHAL DOSE 50; MOLECULAR STRUCTURE; PHOSPHOLIPIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36749093942     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00465-07     Document Type: Article

References (15)

1. Achterberg, V., and G. Gercken. 1987. Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 23:117-122.
2. Avlonitis, N., E. Lekka, A. Detsi, M. Koufaki, T. Calogeropoulou, E. Scoulica, E. Siapi, I. Kyrikou, T. Mavromoustakos, A. Tsotinis, S. G. Grdadolnik, and A. Makriyannis. 2003. Antileishmanial ring-substituted ether phospholipids. J. Med. Chem. 46:755-767.
3. Brachwitz, H., and C. Vollgraf. 1995. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol. Ther. 66:39-82.
4. Croft, S. L., K. Seifert, and M. Duchene. 2003. Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. 126:165-172.
5. Croft, S. L., D. Snowdon, and V. Yardley. 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38:1041-1047.
6. Desjeux, P. 2004. Leishmaniasis. Nat. Rev. Microbiol. 2:692.
7. Eibl, H., and C. Unger. 1990. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev. 17:233-242.
8. Escobar, P., S. Matu, C. Marques, and S. L. Croft. 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81:151-157.
9. Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson, 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2:494-501.
10. Hideshima, T., L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, and K. C. Anderson. 2006. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053-4062.
11. Kapou, A., N. P. Benetis, N. Avlonitis, T. Calogeropoulou, M. Koufaki, E. Scoulica, S. S. Nikolaropoulos, and T. Mavromoustakos. 2007. 3D-quantitative structure-activity relationships of synthetic antileishmanial ring-substituted ether phospholipids. Bioorg. Med. Chem. 15:1252-1265.
12. Olliaro, P. L., P. J. Guerin, S. Gerstl, A. A. Haaskjold, J. A. Rottingen, and S. Sundar. 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis. 5:763-774.
13. Seifert, K., S. Matu, F. Javier Perez-Victoria, S. Castanys, F. Gamarro, and S. L. Croft. 2003. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 22:380-387.
14. Sindermann, H., and J. Engel. 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100(Suppl. 1):S17-S20.
15. Unger, C. T. Maniera, P. Kaufmann-Kolle, and H. Eibl. 1998. In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs Today 34(Suppl. F):133-140.